Literature DB >> 1899849

Responsiveness to phenobarbital in an adult with Crigler-Najjar disease associated with neurological involvement and skin hyperextensibility.

M Persico1, M Romano, M Muraca, S Gentile.   

Abstract

We present the case of a 23-yr-old man who had had since birth marked and sustained unconjugated non-hemolytic hyperbilirubinemia and who had had several attacks of grand mal seizures. Analysis of serum bilirubin by diazoreactive methods showed serum levels of unconjugated bilirubin as high as 445 mumol/L that were not affected by phenobarbital administration. However, analysis of serum bile pigments by high-pressure liquid chromatography demonstrated marked decrease of unconjugated bilirubin after phenobarbital treatment (from 432.4 mumol/L to 291.0 mumol/L) associated with slight increase of bilirubin monoconjugates and disconjugates (from 0.25 mumol/L to 0.42 mumol/L). Furthermore, in the past few years the patient had exhibited striking skin hyperextensibility and diaphragm eventration. This case confirms that alkaline methanolysis-high-pressure liquid chromatography is the most reliable method for assessment of serum fraction bilirubin levels; that clinical parameters such as neurological signs do not unequivocally discriminate between type I and II Crigler-Najjar disease and that response to phenobarbital treatment remains the main diagnostic tool.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1899849

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  2 in total

1.  Crigler-Najjar syndrome type 2: Novel UGT1A1 mutation.

Authors:  Karippoth Mohandas Nair; Peter Lohse; Sheela Nampoothiri
Journal:  Indian J Hum Genet       Date:  2012-05

2.  Acute cholangitis in an old patient with Crigler-Najjar syndrome type II - a case report.

Authors:  Samuel Raimundo Fernandes; Carlos Miguel Moura; Beatriz Rodrigues; Luís Araújo Correia; Helena Cortez-Pinto; José Velosa
Journal:  BMC Gastroenterol       Date:  2016-03-11       Impact factor: 3.067

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.